Drug Trial Radar · NCT06070857
Study of the Safety, Tolerability, and Pharmacokinetics of LV232 Capsules in Chinese Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Oct 5, 2023
Primary completion
Nov 17, 2025
Study completion Nov 17, 2025
Sponsor
- Lead sponsor
- Vigonvita Life SciencesIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study consists of 10 dose groups, 8 subjects in each group (male or female), randomly assigned to study drug or placebo group to evaluate the safety, tolerability and pharmacokinetics characteristics.
Conditions
- Healthy Subjects
Interventions
LV232Drug
Drug: LV232 1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
PlaceboDrug
Placebo:1mg,2mg,4mg,8mg,15mg,25mg,40mg,60mg,90mg and 120mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: 7 days after treatment
- CmaxTime frame: 48 hours after administration
- AUC0-tTime frame: 48 hours after administration
- AUC0-∞Time frame: 48 hours after administration
- AUC0-24hTime frame: 48 hours after administration
- TmaxTime frame: 48 hours after administration
- t1/2Time frame: 48 hours after administration
- CL/FTime frame: 48 hours after administration
- Vd/FTime frame: 48 hours after administration
- KeTime frame: 48 hours after administration
- MRTTime frame: 48 hours after administration
- BPTime frame: 48 hours after administration
- BRPPTime frame: 48 hours after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Xuhui Central Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.